S
S3F
vs
D
DAX Index
Over the past 12 months, S3F has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +1% growth.
Stocks Performance
S3F vs DAX Index
Performance Gap
S3F vs DAX Index
Performance By Year
S3F vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Santhera Pharmaceuticals Holding AG
Glance View
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.